Last 45 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Avadel Pharmaceuticals plc's quarterly P/E stands at 19087.5x. EV/EBITDA has compressed 71.8% YoY to 123.2x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -42.43 | 19087.50 | 22.12 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.44 | 4.99 | 3.22 | 3.60 | 5.02 | 6.31 | 8.14 | 14.25 | 15.59 | 32.81 | 212.74 | — | — |
| — | -21.0% | -60.5% | -74.7% | -67.8% | -80.8% | -96.2% | — | — | — | — | — | — | |
| P/B Ratio | 27.88 | 15.74 | 9.67 | 10.21 | 13.72 | 16.92 | 19.23 | 19.76 | 13.83 | 8.36 | 8.89 | — | — |
| — | -7.0% | -49.7% | -48.3% | -0.8% | +102.5% | +116.3% | — | — | — | — | — | — | |
| P/FCF | — | 16.63 | 17.52 | — | 32.17 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 123.20 | 20.50 | — | — | 436.73 | — | — | — | — | — | — | — |
| — | -71.8% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 152.29 | 23.06 | — | — | 1092.59 | — | — | — | — | — | — | — |
| — | -86.1% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Avadel Pharmaceuticals plc's operating margin was 2.5% in Q3 2025, down 10.5 pp QoQ and up 3.2 pp YoY. The trailing four-quarter average of 0.8% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 18.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.0% | 103.9% | 90.7% | 89.4% | 90.5% | 87.7% | 93.3% | 94.4% | 96.4% | 98.3% | 97.6% | — | — |
| — | +18.4% | -2.8% | -5.3% | -6.2% | -10.8% | -4.4% | — | — | — | — | — | — | |
| Operating Margin | -25.1% | 2.5% | 13.0% | -5.7% | -6.5% | -0.7% | -30.7% | -95.8% | -128.0% | -500.6% | -3311.6% | — | — |
| — | +482.5% | +142.5% | +94.0% | +94.9% | +99.9% | +99.1% | — | — | — | — | — | — | |
| Net Margin | -28.9% | 0.0% | 14.2% | -9.4% | -10.0% | -5.2% | -33.3% | -100.6% | -148.0% | -517.2% | -4307.0% | — | — |
| — | +100.5% | +142.6% | +90.7% | +93.2% | +99.0% | +99.2% | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.4% | 0.0% | 11.7% | -6.7% | -6.8% | -3.6% | -18.6% | -32.9% | -29.1% | -28.6% | -122.7% | — | — |
| — | +100.6% | +163.1% | +79.8% | +76.7% | +87.4% | +84.8% | — | — | — | +49.8% | — | — | |
| ROA | -29.7% | 0.0% | 5.4% | -3.0% | -3.1% | -1.7% | -8.5% | -16.4% | -15.7% | -18.0% | -37.7% | -17.9% | -15.7% |
| — | +100.6% | +164.1% | +82.0% | +80.0% | +90.7% | +77.5% | +7.9% | +0.2% | -35.3% | -12.7% | -58.2% | -79.9% | |
| ROIC | -76.3% | 3.4% | 26.3% | -10.1% | -6.8% | -0.5% | -21.6% | -37.5% | -21.6% | -23.0% | -49.9% | -61.1% | -34.5% |
| — | +732.4% | +222.0% | +73.2% | +68.3% | +97.7% | +56.8% | +38.6% | +37.3% | -29.9% | -175.9% | -343.8% | -255.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Avadel Pharmaceuticals plc's Debt/EBITDA ratio is 12.2x, up from 0.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 7.3% YoY to 2.76x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.38 | 0.03 | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.50 | 0.15 | — | — |
| — | +1363.8% | -2.9% | +27.5% | -22.8% | -94.8% | -80.0% | — | — | — | — | — | — | |
| Debt / EBITDA | — | 12.25 | 0.27 | — | — | 2.74 | — | — | — | — | — | — | — |
| — | +346.7% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.75 | 2.76 | 2.79 | 2.73 | 2.75 | 2.97 | 2.82 | 2.85 | 3.64 | 3.19 | 3.32 | 1.38 | 1.81 |
| — | -7.3% | -1.1% | -3.9% | -24.5% | -6.7% | -15.2% | +106.3% | +101.5% | +16.8% | +22.2% | -62.2% | -80.3% | |
| Quick Ratio | 2.33 | 2.37 | 2.38 | 2.33 | 2.33 | 2.60 | 2.52 | 2.60 | 3.36 | 3.09 | 3.30 | 1.38 | 1.81 |
| — | -8.6% | -5.7% | -10.1% | -30.6% | -15.9% | -23.5% | +88.2% | +85.9% | +13.3% | +21.2% | -62.2% | -80.3% | |
| Interest Coverage | -3.91 | 0.80 | 3.77 | -1.34 | -1.22 | -0.12 | -4.69 | -10.04 | -10.58 | -17.75 | -21.59 | -8.68 | -7.13 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying AVDL stock.
Avadel Pharmaceuticals plc's current P/E is -42.4x. The average P/E over the last 2 quarters is 9554.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Avadel Pharmaceuticals plc's current operating margin is -25.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Avadel Pharmaceuticals plc's business trajectory between earnings reports.